Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SRIKANTH MALEMPATI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1730284456
CMS profile
78966
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$39.13

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $39.13 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $19.61 1
PFIZER INC. $19.52 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SRIKANTH MALEMPATI

NPI 1730284456 · CMS profile ID 78966

Allopathic & Osteopathic Physicians / Internal Medicine

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730284456?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SRIKANTH MALEMPATI, NPI 1730284456, CMS profile ID 78966. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730284456?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SRIKANTH MALEMPATI, NPI 1730284456, CMS profile ID 78966. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730284456?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SRIKANTH MALEMPATI, NPI 1730284456, CMS profile ID 78966, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1730284456?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $39.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $19.6111/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014836801 CMS
PFIZER INC. $17.7510/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050021615 CMS
PFIZER INC. $1.7710/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050107193 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $918.44 52
PY2020 $149.90 9
PY2021 $167.06 8
PY2022 $97.75 5
PY2023 $39.13 3
PY2024 $219.12 11
PY2025 $37.70 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $41,987.06 25
PY2024 Principal investigator $456,514.68 19
PY2023 Principal investigator $11,567.42 11
PY2022 Principal investigator $71,660.40 22
PY2021 Principal investigator $142,254.50 17
PY2020 Principal investigator $136,218.37 28
PY2019 Principal investigator $600,157.35 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ferring International Pharmascience Center US $2,059.20 12/03/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228553
Principal investigator 1 Flexion Therapeutics, Inc. $277,548.25 12/01/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee No dispute reported 06/30/2026 705979747
Principal investigator 1 Bausch Health US, LLC $15,844.00 11/25/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684366499
Principal investigator 1 Bausch Health US, LLC $16,259.00 11/18/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684366227
Principal investigator 1 Bausch Health US, LLC $3,000.00 11/18/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684366231
Principal investigator 1 AbbVie, Inc. $1,025.50 10/30/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
M16-100 No dispute reported 06/30/2026 647591115
Principal investigator 1 GlaxoSmithKline, LLC. $9,225.00 10/23/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
ZOSTER-064 No dispute reported 06/30/2026 669965587
Principal investigator 1 PFIZER INC. $50,400.00 10/12/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671660587
Principal investigator 1 Bausch Health US, LLC $8,545.00 09/20/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684365371
Principal investigator 1 GlaxoSmithKline, LLC. $4,523.40 09/03/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
ZOSTER-056 No dispute reported 06/30/2026 669966609
Principal investigator 1 Bausch Health US, LLC $12,733.00 08/30/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684365025
Principal investigator 1 Bausch Health US, LLC $10,762.00 08/30/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684365027
Principal investigator 1 Ferring International Pharmascience Center US $17,838.00 08/26/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH-INC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228007
Principal investigator 1 Ferring International Pharmascience Center US $8,946.90 08/23/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH-INC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227967
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $50.00 08/15/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426377
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $955.80 08/12/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426373
Principal investigator 1 SANOFI US SERVICES INC. $1,127.00 08/06/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571623
Principal investigator 1 SANOFI US SERVICES INC. $248.00 08/06/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571781
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 08/06/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571787
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 08/06/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571791
Principal investigator 1 SANOFI US SERVICES INC. $156.00 08/06/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571797
Principal investigator 1 PFIZER INC. $38,830.00 08/02/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671660585
Principal investigator 1 AbbVie, Inc. $967.00 07/30/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
M16-100 No dispute reported 06/30/2026 647591113
Principal investigator 1 Ferring International Pharmascience Center US $738.00 07/26/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH-INC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227785
Principal investigator 1 Ferring International Pharmascience Center US $3,060.00 07/02/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH-INC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227581
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $600.00 07/01/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426355
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $300.00 07/01/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426357
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $750.00 07/01/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426359
Principal investigator 1 Bausch Health US, LLC $9,058.00 06/28/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684364183
Principal investigator 1 Ferring International Pharmascience Center US $6,865.20 06/03/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227445
Principal investigator 1 Bausch Health US, LLC $9,222.00 05/31/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684363895
Principal investigator 1 PFIZER INC. $3,877.50 05/21/2019 Non-covered Recipient Entity
Tampa Bay Medical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671622809
Principal investigator 1 AbbVie, Inc. $10,634.80 05/16/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
M16-100 No dispute reported 06/30/2026 647591111
Principal investigator 1 Flexion Therapeutics, Inc. $6,994.00 05/01/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis No dispute reported 06/30/2026 705979745
Principal investigator 1 Bausch Health US, LLC $9,615.00 04/26/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684361189
Principal investigator 1 SANOFI US SERVICES INC. $2,106.00 04/25/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691554249
Principal investigator 1 AbbVie, Inc. $5,190.80 04/16/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
M16-100 No dispute reported 06/30/2026 647591109
Principal investigator 1 Ferring Pharmaceuticals AS $8,387.10 03/26/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655229007
Principal investigator 1 Perrigo Company plc $23,925.00 03/06/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
Bioequivalence study between Perrigo's product and Epiduo Forte Gel No dispute reported 06/30/2026 669933719
Principal investigator 1 Ferring Pharmaceuticals AS $6,156.90 02/20/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228855
Principal investigator 1 Bausch Health US, LLC $6,083.00 02/04/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY No dispute reported 06/30/2026 684348595
Principal investigator 1 PFIZER INC. $48.00 02/01/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671637877
Principal investigator 1 SANOFI US SERVICES INC. $1,352.00 01/22/2019 Non-covered Recipient Entity
Tampa Bay Medical Research
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691545701
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $603.00 01/02/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701426415
Principal investigator 1 PFIZER INC. $48.00 01/01/2019 Non-covered Recipient Entity
TAMPA BAY MEDICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671637879